10-03-2018 – ETBI – EastGate Biotech Receives Approval to Commence a Phase 2 Trial for Liquid Insulin Mouth Rinse Solution Addressing Patient Compliance in the Type 2 Diabetes Market
West Caldwell, New Jersey and Toronto, Ontario--(Newsfile Corp. - October 3, 2018) - EastGate Biotech Corp. (OTC Pink: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes mellitus (T2DM), today announced it received the approval from DRAP (www.dra.gov.pk ) to commence a Phase 2 clinical trial of its oral mouth rinse. The generic name of the insulin mouth rinse is INSUGIN. The primary objectives of the study are to evaluate the safety and tolerability of INSUGIN in Type 2 patients. Secondary objectives are to assess the pharmacokinetic profile, food...
